Lenograstim

Lenograstim is a recombinant granulocyte colony-stimulating factor which functions as an immunostimulator.[1][2] It is developed by Chugai Pharmaceuticals under the brand name Granocyte.

Lenograstim
Clinical data
Trade namesEuprotin, Granocyte, Lenobio, Neutrogin
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
ChemSpider
  • none
UNII
ECHA InfoCard100.207.855
 NY (what is this?)  (verify)

References

  1. "USAN Council. List No. 340. New names. Lenograstim". Clin. Pharmacol. Ther. 52 (1): 112–113. July 1992. doi:10.1038/clpt.1992.117. PMID 1284891.
  2. Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, Muus P, Lefrère F, Berneman Z, Fillet G, Denzlinger C, Willemze R, Leoni P, Leone G, Casini M, Ricciuti F, Vignetti M, Beeldens F, Mandelli F, De Witte T (July 2005). "Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study". Blood. 106 (1): 27–34. doi:10.1182/blood-2004-09-3728. PMC 1895135. PMID 15761020.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.